OncoTherapy Science, Inc.

Business Details

Based on numerous cancer-specific target molecules identified through joint research with the former Institute of Medical Science, The University of Tokyo, the segment conducts drug discovery research and clinical development of small-molecule drugs (OTS167, etc.), cancer peptide vaccines (S-588410, etc.), and antibody drugs (OTSA101, etc.). Revenue consists of upfront payments, milestones, and royalties under collaboration agreements with pharmaceutical companies, and the segment has an investment-heavy structure in which R&D expenses substantially exceed revenue.

Recent Overview

Revenue declined slightly due to lower license income, while operating loss widened due to increased R&D expenses

Segment revenue for FY2026 (ending March 2026) was ¥2 million, a slight decrease of ¥0 million year on year, mainly due to a decrease in income based on license agreements compared to the previous period. On the other hand, in addition to continued basic research and drug discovery research on drug candidate substances, the operating loss expanded to ¥531 million (compared to a loss of ¥487 million in the previous period), mainly due to increased R&D expenses associated with advancing clinical development in the three areas of small-molecule drugs, cancer peptide vaccines, and antibody drugs. Clinical milestones were confirmed, including the completion of patient enrollment for the Phase I trial of OTSA101 in synovial sarcoma in Japan and the completion of the S-588410 Phase III trial in esophageal cancer (no significant difference in the primary endpoint of RFS). Segment assets increased substantially, reflecting funds raised through the issuance of shares.

Key Products

Growth Drivers

• Securing milestone and upfront payment income through new collaboration agreements with pharmaceutical companies
• Expansion of data accumulation and licensing-out opportunities through progress in clinical development of OTS167 (Phase I in breast cancer) and others
• Acceleration of new compound discovery through AI-driven drug discovery joint research with NIBN
• Progress in licensing-out activities for kinase compounds targeting organ fibrosis treatment
• Strengthening of licensing-out activities for antibody drugs, including anti-amyloid beta peptide antibodies
• Expansion of the anticancer drug market (driven by an aging population, increased early detection, spread of molecularly targeted therapies, and advances in cancer precision medicine)

Risks

• The risk that drug development typically takes more than 10 years from basic research to launch, requiring a long period before monetization
• Adverse impact on business performance if collaboration agreements with pharmaceutical companies cannot be concluded, or if existing partnership agreements are terminated
• The risk that clinical trial results may not meet expectations (e.g., no significant difference in the primary endpoint of RFS in the S-588410 Phase III trial for esophageal cancer)
• The existence of material events regarding going concern assumptions due to continued operating losses and negative operating cash flow
• The risk of competition in development speed amid global competition in new drug development
• The risk that R&D expense forecasting is difficult because the party bearing R&D costs varies depending on the terms of collaboration agreements